Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection

Inclusion Criteria: 1. Age \>18 years 2. Confirmed SARS-CoV2 infection by PCR of the nasal/pharyngeal swab, sputum, BAL 3. Onset of the disease symptoms no more than 12 days before the inclusion of the patients in the trial 4. Severe COVID-19 infection as determined with one of the following: * Respiratory rate 30/min * Oxygen Hemoglobin Saturation SAT 93 * CRP \>1.5 (upper normal limit \<0.5) * Ferritin value \>100 * Ratio of PaO2:FiO2 \<300mmHg * Pulmonary infiltrates in Chest X-Ray or Chest CT scan \>50% during 24-48 hours 5. Life threatening infection as determined by one of the following: * Respiratory failure * Septic Shock * Multiple organ failure 6. Signature of informed consent by the patient or legal representative Patients fulfilling criteria 1, 2, 3, 6 and one of criteria 4 or 5 will be eligible for the study. Exclusion Criteria: 1. Critical illness due to progressive COVID-19 with expected survival time \<48 hours 2. Intubated patients \>72 hours 3. Chronic Heart failure NYHA 3 and/or preexisting left ventricular ejection fraction 30% 4. Cardiovascular failure requiring 0.5μg/Kg/min nor-adrenaline or equivalent or more than 2 types of vasopressor medication 5. Liver Cirrhosis Child C 6. Liver failure with bilirubin \>5X ULN and increase of ALT/AST (at least one \>10X ULN) 7. Previous history of allergic reaction to blood or blood products transfusion 8. Known IgA deficiency 9. Pregnancy 10. Breast feeding women 11. Pulmonary edema